OTCMKTS:ATMS Artemis Therapeutics (ATMS) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free ATMS Stock Alerts $0.03 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0852-Week Range$0.11▼$5.00VolumeN/AAverage Volume2,942 shsMarket Capitalization$3.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Artemis Therapeutics alerts: Email Address Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action About Artemis Therapeutics Stock (OTCMKTS:ATMS)Artemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.Read More ATMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATMS Stock News HeadlinesMarch 30, 2024 | seekingalpha.comITRM Iterum Therapeutics plcOctober 10, 2023 | theguardian.comMoon a la mode? Prada to design spacesuit for Nasa’s Artemis III missionMay 13, 2024 | InvestorPlace (Ad)Millionaire investor and Republican donor makes surprising election predictionFind out who Louis believes is going to win the election... And why that will launch a second boom in AI stocksMay 8, 2023 | msn.comMarker Therapeutics gets new chief medical officerApril 27, 2023 | finance.yahoo.comARTEMIS, a soccer-playing humanoid robot, is ready for the pitchApril 23, 2023 | usatoday.comSpaceX Starship, larger and more powerful than Artemis SLS, explodes on first launch attemptMarch 18, 2023 | theguardian.comNasa reveals new spacesuit for Artemis moon landingJanuary 7, 2023 | finance.yahoo.comArtemis Therapeutics Inc. (ATMS)May 13, 2024 | InvestorPlace (Ad)Millionaire investor and Republican donor makes surprising election predictionFind out who Louis believes is going to win the election... And why that will launch a second boom in AI stocksNovember 16, 2022 | cbsnews.comNASA managers order review of hurricane-damaged insulation before moon rocket launchNovember 10, 2022 | msn.comNASA’s Artemis I suffers ‘very minor’ damage from NicoleOctober 10, 2022 | reuters.comArtemis Therapeutics IncSeptember 27, 2022 | yahoo.comArtemis I leaves launch pad ahead of Hurricane IanAugust 18, 2022 | news.yahoo.comNasa’s Artemis 1 moon mission explainedAugust 6, 2022 | yahoo.comNASA's Artemis I moon mission includes educational, cultural, and commemorative mementosJune 2, 2022 | finance.yahoo.comNASA Selects New Instruments for Priority Artemis Science on MoonMay 6, 2022 | msn.comWashington plays key role In NASA's Artemis missionsMarch 25, 2022 | yahoo.comCannes Chooses Former WarnerMedia Exec Iris Knobloch To Succeed Pierre Lescure As PresidentSee More Headlines Receive ATMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous chemical products Sub-IndustryN/A Current SymbolOTCMKTS:ATMS CUSIPN/A CIK1062128 Webwww.artemis-therapeutics.com Phone(646) 233-1454Fax800-253-5177Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,360,000.00 Net Margins-299.54% Pretax Margin-299.54% Return on EquityN/A Return on Assets-425.51% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.12 Sales & Book Value Annual Sales$310,000.00 Price / Sales179.98 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-49.80Miscellaneous Outstanding Shares112,034,000Free Float103,687,000Market Cap$55.79 million OptionableNot Optionable Beta-1.92 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesShimon CitronChief Executive Officer & DirectorHaim TabakChief Operating OfficerDavid DanaChief Financial OfficerDana WolfChief Medical OfficerKey CompetitorsPURE BioscienceOTCMKTS:PUREArch TherapeuticsOTCMKTS:ARTHGT BiopharmaNASDAQ:GTBPBionomicsOTCMKTS:BNOEFIMACNASDAQ:BACKView All Competitors ATMS Stock Analysis - Frequently Asked Questions How have ATMS shares performed in 2024? Artemis Therapeutics' stock was trading at $0.0720 at the beginning of the year. Since then, ATMS shares have decreased by 58.3% and is now trading at $0.03. View the best growth stocks for 2024 here. How do I buy shares of Artemis Therapeutics? Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATMS) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artemis Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
